Palobiofarma — No stage disclosed · €7M

Navarre-based clinical-stage biotech Palobiofarma closed a €7 million round with Inveready (via Inveready Biotech IV), regional public investor Sodena and the founding team; no single lead was named and NTT Data's Fitalent fund exited the cap table. The company says the round could be topped up with up to €5 million from the EIC Accelerator, and the money funds three Phase II trials in COPD, Prader-Willi syndrome and non-small-cell lung cancer.